{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T08:30:32Z","timestamp":1790497832750,"version":"4.1.0"},"reference-count":47,"publisher":"Society of Nuclear Medicine","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Nucl Med"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.2967\/jnumed.118.208611","type":"journal-article","created":{"date-parts":[[2018,4,19]],"date-time":"2018-04-19T20:30:23Z","timestamp":1524169823000},"page":"1234-1242","source":"Crossref","is-referenced-by-count":24,"title":["Radiolabeled Antibodies Against M\u00fcllerian-Inhibiting Substance Receptor, Type II: New Tools for a Theranostic Approach in Ovarian Cancer"],"prefix":"10.2967","volume":"59","author":[{"given":"Emmanuel","family":"Deshayes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riad","family":"Ladjohounlou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Le Fur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Pichard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Lozza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Boudousq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Sevestre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Jarlier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roxana","family":"Kashani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Koch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"Sosabowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Foster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Chouin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Bruchertseifer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfred","family":"Morgenstern","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre-Olivier","family":"Kotzki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Navarro-Teulon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Pierre","family":"Pouget","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1602","published-online":{"date-parts":[[2018,4,19]]},"reference":[{"key":"2021051712121897000_59.8.1234.1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.29210"},{"key":"2021051712121897000_59.8.1234.2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21332"},{"key":"2021051712121897000_59.8.1234.3","doi-asserted-by":"crossref","unstructured":"Jaaback K Johnson N Lawrie TA . Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer. Cochrane Database Syst Rev. 2016;CD005340.","DOI":"10.1002\/14651858.CD005340.pub4"},{"key":"2021051712121897000_59.8.1234.4","first-page":"83","article-title":"Rationale for integrating early postoperative intraperitoneal chemotherapy into the surgical treatment of gastrointestinal cancer","volume":"16","author":"Sugarbaker","year":"1989","journal-title":"Semin Oncol."},{"key":"2021051712121897000_59.8.1234.5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2015.08.172"},{"key":"2021051712121897000_59.8.1234.6","first-page":"45","article-title":"Chemotherapy for intraperitoneal use: a review of hyperthermic intraperitoneal chemotherapy and early post-operative intraperitoneal chemotherapy","volume":"7","author":"Goodman","year":"2016","journal-title":"J Gastrointest Oncol."},{"key":"2021051712121897000_59.8.1234.7","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.112.107540"},{"key":"2021051712121897000_59.8.1234.8","doi-asserted-by":"crossref","first-page":"572","DOI":"10.3892\/etm.2015.2517","article-title":"Pharmacodynamic study of 131I-labeled CA215 antibody on an animal model of estrogen-resistant OC-3-VGH ovarian cancer","volume":"10","author":"Liu","year":"2015","journal-title":"Exp Ther Med."},{"key":"2021051712121897000_59.8.1234.9","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-014-2798-3"},{"key":"2021051712121897000_59.8.1234.10","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.26321"},{"key":"2021051712121897000_59.8.1234.11","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1007\/s00259-010-1639-2","article-title":"177Lu-immunotherapy of experimental peritoneal carcinomatosis shows comparable effectiveness to 213Bi-immunotherapy, but causes toxicity not observed with 213Bi","volume":"38","author":"Seidl","year":"2011","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2021051712121897000_59.8.1234.12","doi-asserted-by":"publisher","DOI":"10.4161\/mabs.2.5.13054"},{"key":"2021051712121897000_59.8.1234.13","doi-asserted-by":"publisher","DOI":"10.1016\/j.nucmedbio.2009.05.004"},{"key":"2021051712121897000_59.8.1234.14","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1016\/S0360-3016(03)00408-5","article-title":"Beta dose-rate distributions in microscopic spherical tumors for intraperitoneal radioimmunotherapy","volume":"56","author":"Syme","year":"2003","journal-title":"Int J Radiat Oncol Biol Phys."},{"key":"2021051712121897000_59.8.1234.15","first-page":"476","article-title":"Indium-111- and yttrium-90-labeled human monoclonal immunoglobulin M targeting of human ovarian cancer in mice","volume":"39","author":"Borchardt","year":"1998","journal-title":"J Nucl Med."},{"key":"2021051712121897000_59.8.1234.16","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1089\/cbr.2000.15.53","article-title":"Intraperitoneal radioimmunotherapy with human monoclonal IGM in nude mice with peritoneal carcinomatosis","volume":"15","author":"Borchardt","year":"2000","journal-title":"Cancer Biother Radiopharm."},{"key":"2021051712121897000_59.8.1234.17","doi-asserted-by":"publisher","DOI":"10.1046\/j.1525-1438.2003.13013.x"},{"key":"2021051712121897000_59.8.1234.18","first-page":"1342","article-title":"Alpha-radioimmunotherapy of intraperitoneally growing OVCAR-3 tumors of variable dimensions: outcome related to measured tumor size and mean absorbed dose","volume":"47","author":"Elgqvist","year":"2006","journal-title":"J Nucl Med."},{"key":"2021051712121897000_59.8.1234.19","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.nucmedbio.2011.07.003","article-title":"Comparison of therapeutic efficacy and biodistribution of 213Bi- and 211At-labeled monoclonal antibody MX35 in an ovarian cancer model","volume":"39","author":"Gustafsson","year":"2012","journal-title":"Nucl Med Biol."},{"issue":"suppl","key":"2021051712121897000_59.8.1234.20","first-page":"3914S","article-title":"Astatine-211-labeled antibodies for treatment of disseminated ovarian cancer: an overview of results in an ovarian tumor model","volume":"9","author":"Andersson","year":"2003","journal-title":"Clin Cancer Res."},{"key":"2021051712121897000_59.8.1234.21","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.117.201285"},{"key":"2021051712121897000_59.8.1234.22","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s13550-017-0283-2","article-title":"Therapeutic efficacy of alpha-radioimmunotherapy with different activity levels of the 213Bi-labeled monoclonal antibody MX35 in an ovarian cancer model","volume":"7","author":"Gustafsson-Lutz","year":"2017","journal-title":"EJNMMI Res."},{"key":"2021051712121897000_59.8.1234.23","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.116.178327"},{"key":"2021051712121897000_59.8.1234.24","doi-asserted-by":"crossref","first-page":"e69613","DOI":"10.1371\/journal.pone.0069613","article-title":"Comparison between internalizing anti-HER2 mAbs and non-internalizing anti-CEA mAbs in alpha-radioimmunotherapy of small volume peritoneal carcinomatosis using 212Pb","volume":"8","author":"Boudousq","year":"2013","journal-title":"PLoS One."},{"key":"2021051712121897000_59.8.1234.25","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.110.080226"},{"key":"2021051712121897000_59.8.1234.26","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.109.066993"},{"key":"2021051712121897000_59.8.1234.27","doi-asserted-by":"crossref","first-page":"491","DOI":"10.2217\/imt.11.11","article-title":"Intraperitoneal radioimmunotherapy: Auger electron emitters for solid tumors","volume":"3","author":"Baranowska-Kortylewicz","year":"2011","journal-title":"Immunotherapy."},{"key":"2021051712121897000_59.8.1234.28","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.02.5973"},{"key":"2021051712121897000_59.8.1234.29","doi-asserted-by":"publisher","DOI":"10.1210\/er.22.5.657"},{"key":"2021051712121897000_59.8.1234.30","doi-asserted-by":"publisher","DOI":"10.1038\/ng1295-382"},{"key":"2021051712121897000_59.8.1234.31","doi-asserted-by":"publisher","DOI":"10.1016\/j.mce.2003.09.006"},{"key":"2021051712121897000_59.8.1234.32","doi-asserted-by":"publisher","DOI":"10.1053\/hupa.2000.18498"},{"key":"2021051712121897000_59.8.1234.33","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2007.09.010"},{"key":"2021051712121897000_59.8.1234.34","first-page":"1583","article-title":"The expression of M\u00fcllerian inhibiting substance\/anti-M\u00fcllerian hormone type II receptor protein and mRNA in benign, borderline and malignant ovarian neoplasia","volume":"34","author":"Song","year":"2009","journal-title":"Int J Oncol."},{"key":"2021051712121897000_59.8.1234.35","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1510604112"},{"key":"2021051712121897000_59.8.1234.36","doi-asserted-by":"publisher","DOI":"10.1042\/bj20031961"},{"key":"2021051712121897000_59.8.1234.37","doi-asserted-by":"publisher","DOI":"10.1016\/S0969-8051(99)00054-2"},{"key":"2021051712121897000_59.8.1234.38","doi-asserted-by":"publisher","DOI":"10.1038\/nprot.2010.13"},{"key":"2021051712121897000_59.8.1234.39","doi-asserted-by":"publisher","DOI":"10.1016\/0022-1759(84)90435-6"},{"key":"2021051712121897000_59.8.1234.40","doi-asserted-by":"publisher","DOI":"10.1088\/0031-9155\/54\/21\/N01"},{"key":"2021051712121897000_59.8.1234.41","unstructured":"Loevinger R Budinger T Watson E . MIRD Primer for Absorbed Dose Calculations. Reston, VA: Society of Nuclear Medicine and Molecular Imaging; 1991."},{"issue":"suppl","key":"2021051712121897000_59.8.1234.42","first-page":"3031s","article-title":"Studies on the red marrow dosimetry in radioimmunotherapy: an experimental investigation of factors influencing the radiation-induced myelotoxicity in therapy with beta-, Auger\/conversion electron-, or alpha-emitters","volume":"5","author":"Behr","year":"1999","journal-title":"Clin Cancer Res."},{"key":"2021051712121897000_59.8.1234.43","unstructured":"Eckerman KF Akira E . MIRD: Radionuclide Data and Decay Schemes. Reston, VA: Society of Nuclear Medicine and Molecular Imaging; 2008."},{"key":"2021051712121897000_59.8.1234.44","doi-asserted-by":"publisher","DOI":"10.3109\/0284186X.2011.582517"},{"key":"2021051712121897000_59.8.1234.45","doi-asserted-by":"crossref","first-page":"064301","DOI":"10.1118\/1.4871617","article-title":"A review of the use and potential of the GATE Monte Carlo simulation code for radiation therapy and dosimetry applications","volume":"41","author":"Sarrut","year":"2014","journal-title":"Med Phys."},{"key":"2021051712121897000_59.8.1234.46","doi-asserted-by":"crossref","first-page":"321","DOI":"10.2174\/1874471011104040321","article-title":"Toxicity and relative biological effectiveness of alpha emitting radioimmunoconjugates","volume":"4","author":"Dahle","year":"2011","journal-title":"Curr Radiopharm."},{"key":"2021051712121897000_59.8.1234.47","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0088239"}],"container-title":["Journal of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.2967\/jnumed.118.208611","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,17]],"date-time":"2021-05-17T20:30:38Z","timestamp":1621283438000},"score":1,"resource":{"primary":{"URL":"http:\/\/jnm.snmjournals.org\/lookup\/doi\/10.2967\/jnumed.118.208611"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,19]]},"references-count":47,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2018,8,2]]},"published-print":{"date-parts":[[2018,8]]}},"alternative-id":["10.2967\/jnumed.118.208611"],"URL":"https:\/\/doi.org\/10.2967\/jnumed.118.208611","relation":{},"ISSN":["0161-5505","2159-662X"],"issn-type":[{"value":"0161-5505","type":"print"},{"value":"2159-662X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4,19]]}}}